Stephen Hoge - 28 Feb 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ James Dillon, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
28 Feb 2025
Net transactions value
-$19,027
Form type
4
Filing time
03 Mar 2025, 16:41:55 UTC
Previous filing
28 Feb 2025
Next filing
29 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise +652 +0.04% 1,450,728 28 Feb 2025 Direct F1
transaction MRNA Common Stock Tax liability $9,824 -316 -0.02% $31.09 1,450,412 28 Feb 2025 Direct F2
transaction MRNA Common Stock Options Exercise +611 +0.04% 1,451,023 28 Feb 2025 Direct F1
transaction MRNA Common Stock Tax liability $9,203 -296 -0.02% $31.09 1,450,727 28 Feb 2025 Direct F2
holding MRNA Common Stock 4,116 28 Feb 2025 By Valhalla, LLC
holding MRNA Common Stock 151,933 28 Feb 2025 By Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -652 -20% $0.000000 2,607 28 Feb 2025 Common Stock 652 Direct F1, F4
transaction MRNA Restricted Stock Units Options Exercise $0 -611 -11% $0.000000 4,884 28 Feb 2025 Common Stock 611 Direct F1, F5
transaction MRNA Stock Option (Right to Buy) Award $0 +238,043 $0.000000 238,043 01 Mar 2025 Common Stock 238,043 $30.96 Direct F6
transaction MRNA Restricted Stock Units Award $0 +148,524 $0.000000 148,524 01 Mar 2025 Common Stock 148,524 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F4 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F5 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F6 25% of this option will vest and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F7 25% of the shares subject to this restricted stock unit award will vest on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.